Scientists at the lab of Professor Hilal Lashuel at EPFL have identified a new enzyme called “TBK1” who plays a central role in regulating the degradation and clearance of the huntingtin protein and introduces chemical modifications that block its aggregation. “We believe that this represents a viable target for the development of possible treatment of Huntington’s disease,” says Lashuel.
- The male Y chromosome does more than we thought
- Ultrapotent compound may help treat C. diff, reduce recurrence
- High-performance single-atom catalysts for high-temperature fuel cells
- Novel neuroimaging study on dissociative symptoms reveals wounds of childhood trauma
- Historical racial & ethnic health inequities account for disproportionate COVID-19 impact